Breast Cancer Research

Feed Category: 

Pubertal timing and breast cancer risk in the Sister Study cohort

Earlier age at menarche is an established risk factor for breast cancer. While age at menarche has been fairly stable over the past half-century, age at breast development (thelarche) has continued to decrease...

Feed Item Url: 
https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-020-01326-2

Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial

Obesity is a risk factor for breast cancer (BC) development, recurrence, and death. In view of this, we aimed to investigate the clinical value of obesity in BC patients treated with anti-HER2 therapies in the...

Feed Item Url: 
https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-020-01356-w

Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study

The global observational BREAKOUT study investigated germline BRCA mutation (gBRCAm) prevalence in a population of patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (...

Feed Item Url: 
https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-020-01349-9

Differential kynurenine pathway metabolism in highly metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression

Immunotherapy has recently been proposed as a promising treatment to stop breast cancer (BrCa) progression and metastasis. However, there has been limited success in the treatment of BrCa with immune checkpoin...

Feed Item Url: 
https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-020-01351-1

Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial

When chemotherapy is indicated in patients with early breast cancer, regimens that contain anthracyclines and taxanes are established standard treatments. Gemcitabine has shown promising effects on the respons...

Feed Item Url: 
https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-020-01348-w